At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 162 enrolled
Drug / intervention
Fingolimoddrug
Likely dose
Fingolimod 0.5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 4-month, Open-label, Multi-center Study to Explore the Safety and Tolerability of Fingolimod 0.5 mg in Patients With Relapsing-remitting Multiple Sclerosis
In Brief
A Phase 3 clinical trial evaluating Fingolimod for Multiple Sclerosis. Completed, enrolled 162 participants across 29 sites in 8 countries.
Detailed Summary
This 4 month, open-label study will evaluate the safety and tolerability of fingolimod 0.5 mg in patients with relapsing-remitting multiple sclerosis (RRMS) and generate additional data in Multiple Sclerosis (MS) patient population that closely resembles the clinical population seen in routine medical care.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesArgentina, Brazil, Colombia, Jordan, Malaysia, Mexico, Panama, Peru
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedDec 2011
Enrollment StartFeb 2012
Primary CompletionApr 2014
TodayJul 2026
First PostedDec 22, 2011
Enrollment StartFeb 1, 2012
Primary CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 14.5 years ago
Interventions
Fingolimoddrug
Fingolimod will be supplied as 0.5mg capsules in bottles of 35.